R
Raul C. Urtasun
Researcher at Cross Cancer Institute
Publications - 86
Citations - 4122
Raul C. Urtasun is an academic researcher from Cross Cancer Institute. The author has contributed to research in topics: Misonidazole & Radiation therapy. The author has an hindex of 37, co-authored 86 publications receiving 3945 citations. Previous affiliations of Raul C. Urtasun include University of Alberta & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial
Wilson Roa,P. M.A. Brasher,Glenn Bauman,M. Anthes,Eduardo Bruera,A. Chan,B. Fisher,Dorcas Fulton,Sunil Gulavita,Chunhai Hao,S. Husain,Amy P. Murtha,Kenneth C. Petruk,Dawn D. Stewart,P. Tai,Raul C. Urtasun,J. G. Cairncross,P. Forsyth +17 more
TL;DR: In view of the similar KPS scores, decreased increment in corticosteroid requirement, and reduced treatment time, the abbreviated course of RT seems to be a reasonable treatment option for older patients with glioblastoma multiforme.
Journal ArticleDOI
A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916).
Lydia T. Komarnicky,Theodore L. Phillips,Karen L. Martz,Sucha O. Asbell,Steven R. Isaacson,Raul C. Urtasun +5 more
TL;DR: Until proven otherwise, the treatment of choice for the majority of patients still remains a conventional palliative course of 3.0 Gy x 10 fractions, and improvement in local control remains an important goal.
Journal ArticleDOI
Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia
TL;DR: Preliminary studies suggest that sensitizer adduct formation in human tumor tissue may be a useful measure of tissue pO2 at the cellular level and that tumor hypoxia might be more related to the rate of tumor growth and histological grading than to tumor size.
Journal ArticleDOI
Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study.
MB Parliament,Chapman Jd,Raul C. Urtasun,Alexander J.B. McEwan,L. Golberg,John R. Mercer,R. H. Mannan,Leonard I. Wiebe +7 more
TL;DR: Preliminary data suggest that the use of gamma-emitter labelled 2-nitroimidazoles as diagnostic radiopharmaceuticals is feasible and safe, and that metabolic binding of 123I-IAZA is observed in some, but not all tumours.
Journal ArticleDOI
Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
Michael D. Prados,Michael D. Prados,W. Seiferheld,W. Seiferheld,Howard M. Sandler,Howard M. Sandler,Jan C. Buckner,Jan C. Buckner,Theodore Phillips,Theodore Phillips,Christopher J. Schultz,Christopher J. Schultz,Raul C. Urtasun,Raul C. Urtasun,Richard L. Davis,Richard L. Davis,Philip H. Gutin,Philip H. Gutin,Terrence L. Cascino,Harry S. Greenberg,Harry S. Greenberg,Walter J. Curran,Walter J. Curran +22 more
TL;DR: An open-label, randomized Phase III trial in newly diagnosed patients with anaplastic glioma other than glioblastoma multiforme comparing external beam radiotherapy (EBRT) plus adjuvant procarbazine, cyclohexylchloroethylnitrosurea, and vincristine (PCV) chemotherapy with or without bromodeoxyuridine (BUdR).